Our mission to ensure scientists and researchers never miss vital research is more important than ever with the world facing the huge challenge of the COVID-19 pandemic. This challenge can only be solved through the work of scientists, academics, clinicians and economists across the world.

Researcher is launching the COVID-19 International Research Collaboration (CIRC) – a dedicated zone on the Researcher platform that provides the easiest way to follow the latest science on COVID-19.

Untitled design

Today CIRC aggregates the papers that have the most engagement from the highest quality users on Researcher and gives the authors of those papers the opportunity to post brief, authoritative updates on how their thinking has changed post-publication. The Coronavirus research on CIRC is split into the following themes:

  • Vaccine
  • Drugs
  • Treatment
  • Drug pathways
  • Sequencing
  • Economic impact
  • Social impact from the Coronavirus
  • Epidemiology
  • PPE

Danilo Euclides Fernandes, a PhD student in Universidade Federal de São Paulo shares:

“I love the main idea of categorising SARS-CoV-2 research into relevant subjects such as drugs, vaccine, etc.
I love CIRC and Researcher is an incredible tool for us to follow recent literature.

“Our lab, headed by Dr Gianna Mastroianni Kirsztajn, researches glomerulonephritis and immunopathological aspects of kidney diseases. Originally, we were running a unique cohort to identify some laboratory aspects among long-term PrEP users. By the end of March, we decided to investigate how the pandemic COVID-19 has affected our patients and also, the drugs they use during SARS-CoV-2 outbreak.”

In addition to launching CIRC, we have collated key numbers that show the increase of output and interest in Coronavirus-related research since January 2020. Top papers and keywords can be found in the full report

twitter

1.5m academics, clinicians, commercial scientists and researchers already use Researcher’s apps and website – but we want to make sure every scientist working to meet the challenge of COVID-19 has access to the latest research about COVID-19.